Article Cited by others

INVITED REVIEW

Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer

Luo Jun

Year : 2016| Volume: 18| Issue : 4 | Page no: 580-585

   This article has been cited by
 
1 Androgen receptor variant 7 (AR-V7) in sequencing therapeutic agents for castratrion resistant prostate cancer
Alessandro Sciarra,Alessandro Gentilucci,Ida Silvestri,Stefano Salciccia,Susanna Cattarino,Susanna Scarpa,Antonio Gatto,Viviana Frantellizzi,Magnus Von Heland,Gian Piero Ricciuti,Francesco Del Giudice,Martina Maggi
Medicine. 2019; 98(19): e15608
[Pubmed]  [Google Scholar] [DOI]
2 Detection of AR-V7 transcript with RNA in situ hybridization in human salivary duct cancer
Hyunseok Kang,Emmanuel S. Antonarakis,Jun Luo,Qizhi Zheng,Lisa Rooper,Angelo M. De Marzo,William H. Westra,Tamara L. Lotan
Oral Oncology. 2018;
[Pubmed]  [Google Scholar] [DOI]
3 Metastatic prostate cancer remains incurable, why?
Liang Dong,Richard C. Zieren,Wei Xue,Theo M. de Reijke,Kenneth J. Pienta
Asian Journal of Urology. 2018;
[Pubmed]  [Google Scholar] [DOI]
4 Nuclear loss and cytoplasmic expression of androgen receptor in penile carcinomas: role as a driver event and as a prognosis factor
Hellen Kuasne,Mateus C. Barros-Filho,Fábio A. Marchi,Sandra A. Drigo,Cristovam Scapulatempo-Neto,Eliney F. Faria,Silvia R. Rogatto
Virchows Archiv. 2018;
[Pubmed]  [Google Scholar] [DOI]
5 Small molecule-induced degradation of the full length and V7 truncated variant forms of human androgen receptor
Kush Dalal,Helene Morin,Fuqiang Ban,Ashley Shepherd,Michael Fernandez,Kevin J. Tam,Huifang Li,Eric LeBlanc,Nathan Lack,Helge Prinz,Paul S. Rennie,Artem Cherkasov
European Journal of Medicinal Chemistry. 2018;
[Pubmed]  [Google Scholar] [DOI]
6 The potential of AR-V7 as a therapeutic target
Takuma Uo,Stephen R. Plymate,Cynthia C. Sprenger
Expert Opinion on Therapeutic Targets. 2018; 22(3): 201
[Pubmed]  [Google Scholar] [DOI]
7 Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer
Yezi Zhu,Adam Sharp,Courtney M. Anderson,John L. Silberstein,Maritza Taylor,Changxue Lu,Pei Zhao,Angelo M. De Marzo,Emmanuel S. Antonarakis,Mindy Wang,Xingyong Wu,Yuling Luo,Nan Su,Daniel Nava Rodrigues,Ines Figueiredo,Jonathan Welti,Emily Park,Xiao-Jun Ma,Ilsa Coleman,Colm Morrissey,Stephen R. Plymate,Peter S. Nelson,Johann S. de Bono,Jun Luo
European Urology. 2017;
[Pubmed]  [Google Scholar] [DOI]
8 Reply from Authors re: Emmanuel S. Antonarakis, Howard I. Scher. Do Patients With AR-V7–Positive Prostate Cancer Benefit from Novel Hormonal Therapies? It All Depends on Definitions. Eur Urol 2017;71:4–6
Julie Steinestel,Christof Bernemann,Andres J. Schrader,Jochen K. Lennerz
European Urology. 2017; 71(1): 6
[Pubmed]  [Google Scholar] [DOI]
9 Prognostic Value of Androgen Receptor Splice Variant 7 in the Treatment of Castration-resistant Prostate Cancer with Next generation Androgen Receptor Signal Inhibition: A Systematic Review and Meta-analysis
Heng Li,Zhize Wang,Kun Tang,Hui Zhou,Haoran Liu,Libin Yan,Wei Guan,Ke Chen,Hua Xu,Zhangqun Ye
European Urology Focus. 2017;
[Pubmed]  [Google Scholar] [DOI]
10 The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
Fouad Aoun,Elie El Rassy,Ghassan Sleilaty,Tarek Assi,Ziad Bakouny,Joseph Kattan
Future Oncology. 2017; 13(30): 2785
[Pubmed]  [Google Scholar] [DOI]
11 Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Jun Luo,Gerhardt Attard,Steven P. Balk,Charlotte Bevan,Kerry Burnstein,Laura Cato,Artem Cherkasov,Johann S. De Bono,Yan Dong,Allen C. Gao,Martin Gleave,Hannelore Heemers,Mayuko Kanayama,Ralf Kittler,Joshua M. Lang,Richard J. Lee,Christopher J. Logothetis,Robert Matusik,Stephen Plymate,Charles L. Sawyers,Luke A. Selth,Howard Soule,Wayne Tilley,Nancy L. Weigel,Amina Zoubeidi,Scott M. Dehm,Ganesh V. Raj
European Urology. 2017;
[Pubmed]  [Google Scholar] [DOI]
12 Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy
Xin Chen,Christof Bernemann,Yuri Tolkach,Martina Heller,Cathleen Nientiedt,Michael Falkenstein,Esther Herpel,Maximilian Jenzer,Carsten Grüllich,Dirk Jäger,Holger Sültmann,Anette Duensing,Sven Perner,Marcus V. Cronauer,Carsten Stephan,Jürgen Debus,Andres Jan Schrader,Glen Kristiansen,Markus Hohenfellner,Stefan Duensing
Urologic Oncology: Seminars and Original Investigations. 2017;
[Pubmed]  [Google Scholar] [DOI]
13 Non-invasive actionable biomarkers for metastatic prostate cancer
Jun Luo
Asian Journal of Urology. 2016; 3(4): 170
[Pubmed]  [Google Scholar] [DOI]

 

Read this article